Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc.（TARS）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · TARS · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
44
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Tarsus Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
TARS 季度内部人买卖趋势
TARS 内幕交易卖出 · TARS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · TARS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
TARS 高管卖出股份 · TARS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 24, 2026 | PYOTT DAVID E I Director | Option | 1,383 | — | Form 4 |
| Mar 20, 2026 | Neervannan Seshadri COO | Sale | 2,989 | $200K | Form 4 |
| Mar 17, 2026 | Whitfield Dianne C. Chief Human Resources Officer | Sale | 4,029 | $280K | Form 4 |
| Mar 18, 2026 | Whitfield Dianne C. Chief Human Resources Officer | Sale | 4,071 | $280K | Form 4 |
| Mar 19, 2026 | Whitfield Dianne C. Chief Human Resources Officer | Sale | 4,174 | $280K | Form 4 |
| Mar 17, 2026 | Wahl Bryan General Counsel | Sale | 4,084 | $284K | Form 4 |
| Mar 18, 2026 | Wahl Bryan General Counsel | Sale | 4,125 | $283K | Form 4 |
| Mar 19, 2026 | Wahl Bryan General Counsel | Sale | 4,231 | $283K | Form 4 |
| Mar 17, 2026 | Neervannan Seshadri COO | Sale | 3,125 | $217K | Form 4 |
| Mar 18, 2026 | Neervannan Seshadri COO | Sale | 3,610 | $248K | Form 4 |
| Mar 19, 2026 | Neervannan Seshadri COO | Sale | 4,589 | $307K | Form 4 |
| Mar 17, 2026 | Mottiwala Aziz Chief Commercial Officer | Sale | 4,286 | $298K | Form 4 |
| Mar 18, 2026 | Mottiwala Aziz Chief Commercial Officer | Sale | 4,330 | $298K | Form 4 |
| Mar 19, 2026 | Mottiwala Aziz Chief Commercial Officer | Sale | 4,440 | $297K | Form 4 |
| Mar 17, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale | 375 | $26K | Form 4 |
| Mar 18, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale | 379 | $26K | Form 4 |
| Mar 19, 2026 | Lin Elizabeth Yeu Chief Medical Officer | Sale | 390 | $26K | Form 4 |
| Mar 17, 2026 | Farrow Jeffrey S See Remarks | Sale | 2,111 | $147K | Form 4 |
| Mar 18, 2026 | Farrow Jeffrey S See Remarks | Sale | 2,133 | $147K | Form 4 |
| Mar 19, 2026 | Farrow Jeffrey S See Remarks | Sale | 2,186 | $146K | Form 4 |
| Mar 17, 2026 | Azamian Bobak R. President/CEO and Board Chair · Director | Sale | 10,972 | $762K | Form 4 |
| Mar 18, 2026 | Azamian Bobak R. President/CEO and Board Chair · Director | Sale | 11,667 | $802K | Form 4 |
| Mar 19, 2026 | Azamian Bobak R. President/CEO and Board Chair · Director | Sale | 11,964 | $802K | Form 4 |
| Mar 16, 2026 | LINK WILLIAM J PHD Director | Sale | 3,629 | $247K | Form 4 |
| Mar 16, 2026 | LINK WILLIAM J PHD Director | Sale | 8,378 | $578K | Form 4 |
Whitfield Dianne C.
Chief Human Resources Officer
日期
Mar 17
股数
4,029
均价
$69.42
总金额
$280K
Whitfield Dianne C.
Chief Human Resources Officer
日期
Mar 18
股数
4,071
均价
$68.71
总金额
$280K
Whitfield Dianne C.
Chief Human Resources Officer
日期
Mar 19
股数
4,174
均价
$67.00
总金额
$280K
Azamian Bobak R.
President/CEO and Board Chair · Director
日期
Mar 17
股数
10,972
均价
$69.42
总金额
$762K
Azamian Bobak R.
President/CEO and Board Chair · Director
日期
Mar 18
股数
11,667
均价
$68.71
总金额
$802K
Azamian Bobak R.
President/CEO and Board Chair · Director
日期
Mar 19
股数
11,964
均价
$67.00
总金额
$802K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 TARS 内幕交易
TARS 内幕交易
Tarsus Pharmaceuticals, Inc.（TARS）内幕交易数据来源于公司内部人（包括Whitfield Dianne C. (Chief Human Resources Officer), Neervannan Seshadri (COO), LINK WILLIAM J PHD (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。TARS内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Tarsus Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
TARS 内幕交易 · 5个问题Tarsus Pharmaceuticals, Inc.（TARS）的内部人包括高管和董事，如Whitfield Dianne C. (Chief Human Resources Officer), Neervannan Seshadri (COO), LINK WILLIAM J PHD (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026